Please assess the completion status of the following clinical trial:

Trial Title: Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 and older, with a physician diagnosis of asthma~* Current non-smoker with \< 10 pack-years smoking history and no smoking within the last year~* Stable asthma control over the last 3 months as defined by Asthma Control Test (ACT) ≥ 20 (40)~* Stable asthma medication regimen over the last 3 months~* FEV1 ≥ 70% predicted~Exclusion Criteria:~* Current smoking or ≥10 pack-years of smoking or any smoking within the last year~* Poor asthma control as defined by ACT\< 20~* Exacerbation of disease within previous 4 weeks~* Recent upper respiratory infection within last 4 weeks~* Acute or chronic rhinosinusitis~* Use of chronic nasal corticosteroids, or any use of nasal corticosteroids during the study~* Concomitant heart, lung or GI disease (liver, peptic ulcer) that would potentially jeopardize the safety of the participant or interfere with interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tauroursodeoxycholic Acid (Type: EXPERIMENTAL): TUDCA 1750 mg daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).